Centessa Pharmaceuticals Limited, formerly Centessa Pharmaceuticals plc, is a clinical-stage pharmaceutical company, developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness, impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It has an early-stage immuno-oncology program focused on its LockBody technology platform. The OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1, NT2 and idiopathic hypersomnia. ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.

Employees

129

Sector

Biotechnology & Medical Research

More about the company

Market Cap	6.27B 5.4B 5.11B 4.63B 8.69B 599B 8.74B 60.72B 23.35B 305B 23.53B 23.02B 962B	P/E 2024	-8.13x	P/E 2025	-17.2x
Enterprise Value	6.09B 5.25B 4.97B 4.5B 8.45B 582B 8.49B 59.01B 22.69B 296B 22.87B 22.37B 935B	EV / Sales 2024	-	EV / Sales 2025	231,810,355x
Free-Float	78.43%	Yield 2024 *	-	Yield 2025	-

06-24	Swiss Market Index Extends Rally; OC Oerlikon Shares Gain	MT
06-24	Eli Lilly Completes Acquisition of Centessa Pharmaceuticals	MT
06-24	Centessa Pharmaceuticals plc(NasdaqGM:CNTA) dropped from NASDAQ Composite Index	CI
06-24	Centessa Pharmaceuticals plc(NasdaqGS:CNTA) dropped from NASDAQ Biotechnology Index	CI
06-24	Eli Lilly and Company completed the acquisition of Centessa Pharmaceuticals plc from Medicxi Ventures (UK) LLP, Index Ventures SA, General Atlantic Service Company, L.P. and other shareholders.	CI
06-23	UK High Court Approves Lilly's $7.8 Billion Acquisition of Centessa	MT
06-22	Centessa Pharmaceuticals plc(NasdaqGS:CNTA) dropped from S&P Global BMI Index	CI
05-26	Eli Lilly to Acquire Three Vaccine Developers for Up to $3.83 Billion	MT
05-20	Eli Lilly Buys Engage Biologics for Up to $202 Million	DJ
05-06	Eli Lilly Plans to Sell About $8 Billion of Bonds to Fund Acquisitions	MT
05-06	Eli Lilly Plans to Sell About $8 Billion of Bonds to Fund Acquisitions	MT
05-06	Centessa Pharmaceuticals plc Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-27	Eli Lilly to Buy Ajax Therapeutics for Up to $2.3 Billion -- Update	DJ

04-20	Wells Fargo Downgrades Centessa Pharmaceuticals ADR to Equal Weight From Overweight, Adjusts Price Target to $42 From $35	MT
04-01	B. Riley Downgrades Centessa Pharmaceuticals to Neutral From Buy, Lifts Price Target to $45 From $42	MT
04-01	Leerink Partners Downgrades Centessa Pharmaceuticals to Market Perform From Outperform, $36 Price Target	MT
12-10	Centessa Set to Redefine Narcolepsy Treatment, Oppenheimer Says	MT
12-10	Oppenheimer Adjusts Centessa Pharmaceuticals PT to $62 From $40, Maintains Outperform Rating	MT

06-23	Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales	GL
05-11	Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA	BU
04-01	Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA	BU
03-31	Are APLS, CNTA, BIRD Obtaining Fair Deals for their Shareholders?	PR
03-31	CNTA Stock Alert: Halper Sadeh LLC is Investigating Whether Centessa Pharmaceuticals plc is Obtaining a Fair Price for its Shareholders	BU

04-01	Morning Meeting: Ahora el petróleo es vuestro problema
04-01	Wall Street termine en hausse, rassurée par les propos de Washington et Téhéran
03-31	Trump maintient Téhéran sous pression et griffe ses alliés... Wall Street apprécie
03-31	Wall Street ouvre en nette hausse, veut croire à une désescalade au Moyen-Orient
03-31	Hausse attendue des indices américains avant le rapport JOLTS, le conflit au Moyen-Orient s'enlise

Centessa Pharmaceuticals plc Stock Deutsche Boerse AG

Stocks

260

US1523091007

Biotechnology & Medical Research

Valuation : Centessa Pharmaceuticals plc

Chart: Centessa Pharmaceuticals plc

Latest news : Centessa Pharmaceuticals plc

Analysts' recommendations : Centessa Pharmaceuticals plc

Press Releases : Centessa Pharmaceuticals plc

News in other languages : Centessa Pharmaceuticals plc

Quotes and Performance

Managers and Directors : Centessa Pharmaceuticals plc

Other Biotechnology & Medical Research

Financials

Company Profile

Manager	Title	Age	Since
Charlene Stoudt CTO	Chief Tech/Sci/R&D Officer	-	01/10/2024
Tia Bush CTO	Chief Tech/Sci/R&D Officer	55	01/03/2023
David Chao ADM	Chief Administrative Officer	58	01/04/2021

Director	Title	Age	Since
Christopher Stokes BRD	Director/Board Member	-	24/06/2026
Kristina Wright BRD	Director/Board Member	-	24/06/2026

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CENTESSA PHARMACEUTICALS PLC	+1.17%	+3.59%	-	-	6.27B
LONZA GROUP AG	-0.71%	-6.35%	-4.87%	+9.03%	46.05B
REVOLUTION MEDICINES, INC.	+0.21%	-2.98%	+340.68%	+519.93%	43.59B
IQVIA HOLDINGS INC.	+1.74%	-2.24%	+37.28%	+21.57%	42.35B
BEONE MEDICINES AG	+1.38%	-3.28%	+3.23%	+65.60%	38.86B
CELLTRION, INC.	-1.44%	-5.26%	+8.78%	+36.85%	32.24B
ASCENDIS PHARMA A/S	+0.87%	-2.60%	-	-	17.16B
MEDPACE HOLDINGS, INC.	+0.75%	-0.64%	+18.07%	+110.32%	16.28B
EUROFINS SCIENTIFIC SE	-0.31%	-2.78%	+10.47%	+30.49%	14.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.93%	-3.55%	+74.20%	+39.37%	13.03B
Average	+0.56%	-4.23%	+60.98%	+104.14%	29.32B
Weighted average by Cap.	+0.42%	-4.51%	+73.05%	+123.51%

	2024	2025
Net sales	-	15 12.92 12.24 11.09 20.81 1.43K 20.91 145.34 55.89 729.06 56.33 55.1 2.3K
Net income	-236M -203M -192M -174M -327M -22.52B -329M -2.28B -878M -11.46B -885M -866M -36.21B	-198M -170M -161M -146M -274M -18.87B -275M -1.91B -736M -9.6B -742M -726M -30.34B
Net Debt	-364M -314M -297M -269M -505M -34.81B -508M -3.53B -1.36B -17.71B -1.37B -1.34B -55.96B	-176M -152M -144M -130M -244M -16.83B -246M -1.71B -657M -8.56B -662M -647M -27.06B